Sanara MedTech posts 10th record quarter, CEO transition By Investing.com

Sanara MedTech Inc. (SMTI), a company specializing in surgical and wound care products, announced its first-quarter results for 2024, marking its 10th consecutive record quarter with revenues reaching $18.5 million. Amidst this financial growth, the company also navigated a change in leadership, with Ron Nixon stepping in as the new CEO following Zach Fleming’s resignation.

Despite concerns that such a transition could affect operations, Sanara MedTech assured stakeholders that sales momentum remains strong, and the departure of sales leader Seth Yon is not expected to cause disruptions. The company is actively seeking partnerships to advance its Tissue Health Plus strategy and has bolstered its financial position through a new debt facility with CRG.

Key Takeaways

• Sanara MedTech achieved a record $18.5 million in revenue for the first quarter of 2024.
• Ron Nixon has taken over as CEO after Zach Fleming resigned.
• The company is expanding its product offerings and pursuing partnerships for its Tissue Health Plus strategy.
• Sanara MedTech has secured a new debt facility to support growth and potential acquisitions.
• Sales momentum remains strong despite the CEO transition and the upcoming departure of sales leader Seth Yon.
• A minor decrease in bone fusion product sales was noted, attributed to inventory timing and supply issues.
• The company aims to partner with strategic and financial partners for Tissue Health Plus by the end of 2024.
• New appointments include Tyler Palmer for corporate development and Jake Waldrop as Chief Operating Officer.
• Sanara MedTech is focused on long-term value over short-term profitability, as indicated by the willingness to invest in growth opportunities.
• A higher net loss in 2024 was reported, due to changes in the fair value of earn out liabilities and increased amortization of intangibles.

Company Outlook

• Sanara MedTech is focused on expanding its surgical sector offerings.
• The company is exploring partnerships to execute its Tissue Health Plus strategy by the end of 2024.
• New corporate development and operations appointments have been made to support anticipated growth.

Bearish Highlights

• The bone fusion product line saw a slight decrease in sales, which was linked to timing and supply disruptions.

Bullish Highlights

• The company has achieved its 10th consecutive record quarter.
• Sales momentum remains unaffected by the CEO transition and the upcoming departure of a key sales leader.

Misses

• Despite record revenues, the company reported a higher net loss in 2024 compared to previous periods.

Q&A Highlights

• CEO Ron Nixon emphasized stability in sales and leadership, indicating no imminent changes in his position.
• The company is prioritizing long-term value creation over immediate profitability, as evidenced by its strategic planning and recent executive hires.

Sanara MedTech Inc. continues to navigate through a period of both opportunity and transition, maintaining a focus on strategic growth and long-term shareholder value. The company’s clear message to the market is one of resilience and ambition, as it seeks to expand its footprint in the surgical and wound care sectors. With a new CEO at the helm, Sanara MedTech is poised to leverage its strengthened financial position and robust product pipeline to secure a competitive edge in the healthcare industry.

InvestingPro Insights

Sanara MedTech Inc. (SMTI) has shown a remarkable gross profit margin of 88.8% over the last twelve months as of Q1 2024, reflecting the company’s ability to retain a significant portion of its sales revenue after accounting for the cost of goods sold. This high margin is a testament to the company’s efficient production and service delivery in the surgical and wound care markets.

In terms of stock performance, the company has experienced a notable decline, with a 1-week price total return of -12.6% as of the 135th day of 2024. This sharp drop may have caught the attention of value investors, as the Relative Strength Index (RSI) suggests the stock is currently in oversold territory. Investors interested in potential rebound opportunities might consider this an intriguing entry point.

Despite these fluctuations, Sanara MedTech has not been profitable over the last twelve months, with a negative P/E ratio of -49.91, adjusting to -32.78 for the same period. This highlights the challenges the company faces in achieving profitability amidst its growth and expansion efforts.

For those looking for more insights, there are additional InvestingPro Tips available for SMTI, which delve deeper into the company’s financial health and stock performance. By using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable tips. Visit https://www.investing.com/pro/SMTI to explore the full suite of analytical tools and tips, including 6 more tips that could help inform your investment decisions.

Full transcript – Wound Mgmt Tech (SMTI) Q1 2024:

Operator: Greetings, welcome to the Sanara MedTech Inc. First Quarter Results and Business Update Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Callon (NYSE:) Nichols, Director of Investor Relations at Sanara MedTech. Callon, you may begin.

Callon Nichols: Thank you and good morning, everyone. I’d like to welcome you to the Sanara MedTech’s earnings conference call for the quarter ended March 31, 2024. We issued our earnings release yesterday morning, and I would like to highlight that we have posted today’s deck on the investor relations page of our website. This supplemental deck, as well as a copy of the earnings release and the Form 10-Q for the quarter ended March 31, 2024 are also available on this page. We will reference this information in our remarks today. With us today are Ron Nixon, our Executive Chairman and CEO, Mike McNeil, our Chief Financial Officer, and Seth Yon, our President, Commercial. Please note that certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risk and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factor set forth in our most recent Annual Report on Form 10-K, as supplemented by the risk factors in our most recent quarterly report on Form 10-Q. Also, this conference call, our earnings release, and supplemental deck reference certain non-GAAP measures. In that regard, I direct you to the reconciliation of these measures and the earnings materials that are available on our website. Now I’d like to turn the call over to Ron.

Ron Nixon: Thank you, Callon, and good morning, everyone. As we mentioned in our press release yesterday, our former CEO, Zach Fleming, resigned on Friday. We’re in the process of finalizing a separation agreement with Zach and I’ve been appointed CEO by the company’s Board of Directors. As a result of Zach’s departure, the company will no longer be presenting the proposal for the election of a ninth director on our Board of Directors at the annual meeting of shareholders in June. As many of you know, I’ve been intimately involved with the leadership team in developing and executing Sanara’s strategic vision, since the inception of Sanara MedTech. And I’m looking forward to working with the Sanara’s leadership team now on a daily basis to continue that execution. Turning to our first quarter results, first quarter of 2024 was the company’s 10th consecutive record quarter. The company generated $18.5 million in revenue in Q1 over the course of 2023. In 2023, we made significant advancements in data analytics, sales force optimization, and sales processes. As I’ve told many of you before, when you’re in a high-growth business, you need to be able to build infrastructure, data analytics, and details around these processes in order to be able to improve to continue that growth. We believe that that’s been implemented and that will pay dividends going forward. These improvements and the momentum we’ve achieved in the fourth quarter helped us to exceed our forecast for the first quarter. And we believe positioned us to continue to build upon the success the teams achieved in previous periods. For the three months ended March 31, 2024, company had a net loss of $1.8 million while we generated positive adjusted EBITDA of $300,000 over the same period. I would like to provide a brief update on our partnership with InfuSystem. We continue to invest in this partnership and are focused on three potential areas of opportunity. The first initiative for the partnership is to distribute Sanara’s advanced wound care products including BIAKŌS and HYCOL, as well as negative pressure wound therapy products into long-term care, skilled nursing facilities, and wound centers. Building upon the strategic objectives, we’re also exploring emerging opportunities for entry system to distribute our advanced wound care products outside of this channel. We also believe that our partnership will play a key role in Tissue Health Plus, our value-based care strategy that you’ve heard about many times before, which is planned to include standardized wound prevention and treatment plans that utilize Sanara’s wound care products. As these opportunities continue to develop, we will provide additional updates. And as I mentioned in our last call, we’re having discussions with potential partners participating in the execution of the Tissue Health Plus strategy. During the process, we’re continuing to invest in the technology capabilities and infrastructure that we believe are required to commercialize this very well-designed strategy. But we do not anticipate that this will continue spending by us alone in 2024, and we hope to have our partnerships in place so that we can execute and these partners we are looking for are not just financial partners, they are strategic partners. We are also continuing focusing expansion of the existing surgical product offering. Lastly, we made significant progress in the area of intellectual property and manufacturing processes for Cellerate product line itself. We think that this has been something we’ve talked about for many times and we believe that it’s got a significant ability for us to be able to get more IP around the product as we continue to advance this through many of the different specialties. I can now introduce you to Seth Yon, our President of Commercial. Seth has been with the company since 2018, and over the years has been promoted multiple times to roles of increasing responsibility. In his current position as President, Commercial, he leads our national sales team and multiple internal teams, including marketing, customer support, national accounts and business operations. He’s been instrumental in building out our sales team and infrastructure scenario, and I look forward to working closely with him on the execution of our strategy. Seth, I’ll turn it over to you to discuss our surgical sales results in more detail.

Seth Yon: Thanks, Ron. In the first quarter of 2024, our products were sold in over 1,082 facilities across 34 states and the District of Columbia. We continue to focus on increasing the use of our products in new and existing territories, expanding usage into new specialties, and increasing our per-facility sales. Our products were approved to be sold in more than 3,000 facilities as of March 31, 2024. Subsequent to the end of the quarter, a new contract with a large GPO went into effect, which has had a significant impact on the number of facilities in which our products are approved to be sold. Sales of our soft tissue products grew from $12.9 million in the first quarter of 2023 to $16.1 million in the first quarter of 2024. Sales of bone fusion products decreased slightly from $2.6 million in 2023 to ($2.5 million) (ph) in 2024. This was due to a slower than expected adoption of ALLOCYTE Plus, as well as a larger than normal order from a facility in Q1 of 2023 of (biofilm) (ph), which subsequently returned to previous levels in subsequent quarters. I will now turn it over to Mike McNeil to discuss the details of our recent loan agreement with CRG, as well as our most recent financial results. Mike.

Mike McNeil: Thank you, Seth. I’d like to discuss the new debt facility we recently announced with CRG. This transaction helped us strengthen our cash position and provided access to growth and acquisition capital in a way that was non-dilutive to equity holders. The facility allows for flexibility in the event of a transaction we believe would be accretive, given the fact the company has the ability to draw additional capital beyond the initial ($15 million) (ph) at our option. We are currently in discussions with the commercial bank for an additional $10 million revolver as permitted under the CRG facility which could give us access to what we expect will be lower cost capital for any immediate needs. The term loan is structured as a senior secured loan with a five-year term and up to $55 million in aggregate potential proceeds. In addition to the $15 million drawn at close, we can draw up to an additional $40 million before June 30, 2025. I’ll now go into more detail about our most recent financial results for the three months ended March 31, 2024 scenario generated net revenue of $18.5 million compared to $15.5 million for the first quarter of 2023, a 19% increase over the prior year period. A higher revenue in 2024 was due to increased sales of our soft tissue repair products, including CellerateRX, as a result of increased market penetration, geographic expansion, and our continuing strategy to expand independent distribution network in both new and existing US Markets. SG&A expenses for the first quarter of 2024 were $16.2 million compared to $13 million for the same period in 2023. The higher SG&A expenses in the first quarter of 2024 were primarily due to higher direct sales and marketing expenses, which accounted for approximately $2.2 million, or 69% of the increase compared to the prior year period. The higher direct sales and marketing expenses were primarily attributable to an increase in sales commissions of $1.6 million as a result of higher product sales and $0.6 million of increased costs as a result of sales force expansion and operational support. R&D expenses for the three months ended March 31st were $0.9 million compared to $1.3 million for the same period in 2023. The lower R&D expenses in 2024 were primarily due to lower costs associated with the precision healing diagnostic imager and LFA. Sanara had a first quarter net loss of $1.8 million compared to a net loss of $1.2 million during the same period in 2023. The higher net loss in 2024 was due to higher SG&A costs and higher amortization of our acquired and tangible assets, partially offset by higher gross profit and lower R&D expenses. Our cash on hand at the end of the quarter was $2.8 million. With that, I’ll turn it back to Ron for some closing remarks.

Ron Nixon: Thanks, Mike. We’re pleased with our progress in the first quarter, continued growth and results that we had in that first quarter. We obviously are striving to seek profitability. This is not a revenue play. This is a play to build a business and build it for the long term. And we plan to do so. Related to our surgical business, we’ve had multiple opportunities that we continue to review that complement our existing product offering, we continue to expand our products into other areas of specialty as well as other hospitals. You know how many hospitals we are in today and we want to continue to advance that across the U.S. This concludes our remarks and we look forward to answering any questions you may have. Operator, we’re ready to open the calls for questions.

Operator: Thank you. At this time we’ll be conducting a question-and-answer session. (Operator Instructions) And we did have a question coming from Ian Cassel from IFCM. Ian, your line is live.

Ian Cassel: Yeah, Ron, I just had one question, I can jump back in the queue. My question was the recent CEO transition, has that transition disrupted the sales momentum you’ve shown through Q1?

Ron Nixon: Not at all. I will tell you, Ian that the team is stronger than it’s ever been. Seth Yon has been driving this for a long period of time. And the sales team is — we’re sorry to see him go, but quite frankly, there’s zero disruption.

Ian Cassel: Okay a follow-up question, maybe for Seth. You know, I noticed that the bone fusion products, they’ve been kind of flat year-over-year. I was wondering if you could maybe speak to that since I believe the supply disruption kind of became debated in Q4.

Seth Yon: Sure as I mentioned earlier, we did have a little bit of softening as we returned with ALLOCYTE Plus. And I do believe a lot of that is related to timing. As you can imagine when you have an issue with inventory, that inventory then becomes an issue and it’s replaced at a facility level with something else. And so we had to start that cycle, that process again, to get that product back in and get re-engaged with our distributors as well and that cycle that process has taken a little bit longer than we had expected.

Ian Cassel: Thank you.

Operator: Thank you. There were no other questions from the lines at this time. (Operator Instructions) Okay, we did have Ian Cassel come in with a follow-up. Ian, your line of live.

Ian Cassel: When we think about the Tissue Health Plus and partnering on that, is that — and I was trying to remember what you said in prepared remarks, but is that something you expect hopefully to happen by the end of 2024, being able to have some partnerships for that?

Ron Nixon: Yes, it is what we anticipate. So Ian, what we have done is we have designed a really thoroughly thought out strategy for how you approach value based in wound care. And actually no one has ever actually done this. So it is complicated because you’ve got payers, you’ve got providers, you’ve got products, you’ve got patients traveling through the continuum. So there’s the issue of where do you take care of these patients, because they’re in the home setting, they’re in home care, they’re in SNFs, they’re in (LTACs) (ph). And because of all the discussions we’ve had historically about how episodic care does not fit well with the wound from — just from a timing standpoint, you have typically the focuses on the primary comorbidity that gave rise to that wound. And so you really have to think through how do we catch this in its journey? How do we build a platform that will allow for us to have continuous monitoring of that patient, but also have care coordination and navigation to be able to work through this. So when you think of all those steps, those are ideal partners that we would look for to participate with us, and that would be a financial partner as well as a partner that brings some value add to our overall strategy.

Ian Cassel: Okay. And maybe a follow-up, you’re now CEO of the company. Do you view this as a temporary thing or do you see yourself staying in (here permanently) (ph)?

Ron Nixon: You know, it was a temporary thing when I started and spent 2.5 years in the seat. I’m actually in the seat every day, and there is not a day go by that I’m not talking to somebody from Sanara. So really, from my perspective, it’s just a better line of communication for me to everyone. And we’re going to just onward and upward, and I’m looking forward to the journey. And I have no plans to change out of this position anytime soon, unless something unforeseeable happens. And so I’m trying to dodge as many cars as I can, et cetera. So something doesn’t happen, but I’m looking forward to it. This is my passion. This was originally my concept of what we wanted to go do and build this business. And I think we’ve done a remarkable job and it’s only from one thing. It’s not me, it’s because we have people that are highly competent, that are passionate about what we do, and they’re in our company. And I don’t see anybody that doesn’t have that passion continuing and going forward for the execution of our strategy.

Ian Cassel: And maybe to that, maybe to that — you recently announced adding two more folks to the management team. Can you talk about why you brought them on board and your experience working with them?

Ron Nixon: Absolutely, we have a great team to begin with, but what you have to do is you’re going through these growths and we’re anticipating higher growth, So when you anticipate higher growth, you have to have more people in the seat. And we look at a lot of opportunities. So we felt like we needed a dedicated corporate development person that also has got a strategic background. And so that’s Tyler Palmer that joined us. He’s got a longstanding experience in wound care. And then we also need that operational focus with somebody that’s also got financial strength to complement what we do. And that’s Jake Waldrop, and Jake and I have worked together for many years, and he came out of the ortho business in the lower extremity ortho space, and he understands it really well. And he is a former Chief Financial Officer that adapted real well to being a Chief Operating Officer. So we are delighted to have both of those in our camp. But what we also don’t talk about is just all the other new people that come on to support all of this in our sales effort, the new trainees that come on board from the sales side that all are just remarkable and we’re excited about coming on because we just keep getting more laser focused on what our needs are. And with those needs, we go identify the right kind of people. And if you’ve got a good strategy in a growth company, people that are high performers seek you out. And so I’m very positive about where we are going and I feel very good about the depth of the team. And this is not stopping. We’ll continue to advance the depth of the team in order to keep up always with the infrastructure. As I’ve always said, companies go up, they’ve got to go sideways to build infrastructure and support so that they don’t collapse, then they go back up again. It’s a journey and it just continues to happen and that’s how you can build greatness.

Ian Cassel: Okay, thanks Ron.

Ron Nixon: Thank you, Ian.

Operator: Thank you. (Operator Instructions) And while we wait for any other questions, we did have a couple come in from the web. And can you speak to the profitability in relation to the revenue increasing or indeed decreasing but the profitability taking a step back? And then also can you share some color around the SG&A increase and how it appears to be increasing as fast or faster than the revenue quarter-over-quarter?

Ron Nixon: Yeah, so I will start by speaking to the lumpiness of how costs come in and that is depending on how we’re hiring, depending on how we are advancing sales. As you know, in our SG&A, a big variable in the SG&A is commissions paid. That correlates very well with more sales coming in. And Mike, I’ll let you talk about it in just a second. But as you think about the business, we are striving for profitability. We achieve profitability, although in a minor way. That’s not where we want our levels to be. But what we also have to balance is that when we see opportunities that we think are a really good opportunity for our shareholders long-term and building value, we don’t want to be prudent and make sure that we’ve got adequate capital, that if we’re going to take a bet on something that we believe will add significant value to us. We just need to make sure that we have a level of cash available to us to be able to do that, which means that we might forgo some period of time for profitability if we know it’s going to be a multiple of that from the investment that we made. But operational efficiency, sales efficiency, and profitability are all top of mind. Mike, is there anything else you’d like to add?

Mike McNeil: Yeah, thanks Ron. I would just like to add, 2023 included a couple benefits to the P&L such as change in fair value of earn out liabilities. We had a big credit last year we didn’t have this year. And then also the amortization of our intangibles went up significantly. And that really accounts for the higher net loss in 2024.

Ron Nixon: Thank you, Mike.

Operator: Okay. There were no other questions in queue at this time. I would now like to hand the call back to Ron Nixon for closing remarks.

Ron Nixon: Okay. Thank you very much. We thank all of our shareholders for being on the call today. It is besides the people in our firm, the shareholders matter a lot. We love the continued support that you’ve given us. And thank you very much for the support through this transition. As we said, we do not believe it will be disruptive at all, but many of you have called to talk about your confidence with our firm, and we thank you for that and greatly appreciate it. So thank you very much. We look forward to talking to our shareholders in the near term. Take care.

Operator: Thank you. This does conclude today’s conference. You may disconnect your lines at this time. Thank you for your participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.